Neurotech International Ltd. · ASX:NTI
Neurotech International — Investor Presentation (January 2019)
28 slides from Neurotech International's investor presentation, Jan 29, 2019
Slide 1: Bridging to a better life
Bridging to a better life Investor Presentation Strategic Review and Capital Raise Neurotech International Limited (ASX: NTI) | 29 January 2019
Slide 2: Disclaimer
Disclaimer IMPORTANT INFORMATION Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech Int
Slide 3: Overview
Overview • Neurotech is focussed on the development & commercialisation of neurological solutions that improve quality of life • Our flagship Mente device and therapy is the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with e
Slide 4: Highly Experienced Board & Advisers
Highly Experienced Board & Advisers Peter O’Connor • Deep experience in global funds management, asset allocation & manager selection advisory Chairman (Non-Exec) • Held senior public company directorships (UK, Canada & Australia) MA, Barrister-at Law • Non-executive director of Northern Star Resour
Slide 5: New Strategic Direction
“It’s pleasing to see the renewed focus and energy in the company. The strategy of enabling clinics with the Mente therapy and building on the unique values with artificial intelligence and software automation is where I believe Mente can really make a difference in the world." Dr Adrian Attard Trev
Slide 6: New Model Strategic Highlights
New Model Strategic Highlights Steady Recurring Revenue Significantly Broadened Lower Adoption Barriers & Reduced Reliance on with Pathway to Significant Market Beyond Autism Clinics are Aligned to Grow Distributors Growth Revenue • The new subscription model envisages • Mente will be repositioned a
Slide 7: Our Vision
Our Vision Bringing clinical grade, personalised neurotherapy into the home and school environment, making it affordable and accessible to We achieve this through those who need it. enabling and empowering clinicians and therapists to Increasing availability deliver tailored and proven Enhancing the
Slide 8: Our Product is
Our Product is The world’s first home-based brain training therapy that is clinically proven to Proven increase engagement & improve relaxation in autistic children with elevated delta band brain activity Each Mente device analyses the individual’s EEG & delivers personalised Adaptive brain training
Slide 9: Science Supported by Positive Feedback
Science Supported by Positive Feedback In 2018, a US independent, double-blinded clinical trial for “My hopes were boosted autistic children found: when I heard his first word – “father”. I will continue to • Significant reductions in abnormal levels of use Mente Autism – within “After 10 days of us
Slide 10: Market Opportunity
Market Opportunity Neurotech continues to be positioned … & our addressable market is much broader between two growing trends of interest in than autism neurotechnology & technology-enabled • While the 2018 clinical study focussed on children with autism, its home care… findings & the existing Mente
Slide 11: Target Buyer
Target Buyer The market entry strategy will funnel from a targeted but sufficiently broad marketing campaign that focuses on clinics and therapists involved with early learning difficulties, playing into the behavioural traits (lack of attention, engagement) that Mente is seeking to modulate. • The
Slide 12: Scale and Accelerate from Early Usage Success
Scale and Accelerate from Early Usage Success Mente Active Users “The interest in Mente has been incredible and global following our publication of our clinical trial. We receive comments and notes from physicians throughout the world asking about obtaining Mente for their patients. There is a speci
Slide 13: New Subscription Model & Clinic Approach
New Subscription Model & Clinic Approach … based on intensive internal review and external feedback The patients receives the Neurotech sells clinic headband from the clinic bundles at US$5 – Therapy sessions are as part of a wider 10/session, price added to a pool held treatment plan depending on p
Slide 14: Subscription Model – Example Pricing For Clinics
Subscription Model – Example Pricing For Clinics Starter Packs • Includes headbands and an embedded requirement for clinics and clinicians to be trained and certified €499 €2,250 €4,500 Patient Pack Clinic 5 Pack Clinic 10 Pack • Designed to cover the cost of headband (€300) and a portion of loaded
Slide 15: Our Strategic Horizons
Our Strategic Horizons HORIZON 3 Deliver better, multi-faceted product at lower cost 12 - 24 months HORIZON 2 Expand geographies, expand treatment protocols SENSOR HARDWARE & 3 - 18 months PARTNERSHIPS HORIZON 1 • Reduce manufacturing costs from Prove Go To Market (GTM) model €300/unit to €280/unit
Slide 16: Near Term Projects and Milestones
Projects & Milestones Underway Update of cloud data New website with Fulfilment / support / model & web apps online purchase systems integration to enablement / UK support new strategy Near Term Projects and Milestones product launch Messaging Pilot outreach to updates & website Clinician onboarding
Slide 17: In Summary…
In Summary… ““The combination of neuro-assessment, neurofeedback and methods of brain entrainment which Mente delivers, uses powerful and state-of-the art techniques to facilitate clinical providers in the field of mental wellness to offer tools for their clients and make many of these tools conveni
Slide 18: Capital Raise
Capital Raise
Slide 19: Capital Raising Overview
Capital Raising Overview • Neurotech is seeking to raise up to A$3.3 million at 3 cps via a 1 Potential Uptake 50% 75% 100% for 1 renounceable rights issue to fund operations for the next Existing Shares 109,620,903 109,620,903 109,620,903 12 months New Shares issued 54,810,452 82,215,677 109,620,90
Slide 20: Capital Raising Indicative Timetable
Capital Raising Indicative Timetable Item Indicative Date Announcement of Offer and lodgement of Offer Documents with ASIC and ASX Tuesday, 29 Jan Shares quoted on a “ex-rights” basis and rights trading commences Friday, 1 February Record Date to determine entitlements (5pm, WST) Monday, 4 February
Slide 21: Appendix
Appendix
Slide 22: Our Journey
Our Journey We have spent the last five years refining & validating Mente. Product Mente Mente Autism Mente 2 version 1 first Release released released In the near term, we are Mente design focussed on: Further Mente simplified & improved Enhanced reporting & US clinical trial results • Leveraging p
Slide 23: The Science Behind Mente
The Science Behind Mente Personalised & tailored therapy… On hearing the binaural beats, brainwave activity A closed loop is created by monitoring resulting • Recognising that each person is unique & every day is different, Mente takes is tuned into a desired brainwaves, then the individual’s unique
Slide 24: Applied Clinical Research leads R&D
Applied Clinical Research leads R&D • Mente has successfully obtained its clinical validation against placebo units as part of the US Clinical Trial, providing the scientific foundation to enable the commercial rollout to clinics in the near term • We envisage further discussions with clinical and u
Slide 25: Existing Distributors
Existing Distributors • In the 0 – 6 month horizon, our focus will be on enabling and supporting clinical practices and building referral networks directly, such that we learn and improve the system • Over the 3 – 18 month horizon, we anticipate selected regional partners will operate virtual clinic
Slide 26: Key Risks
Key Risks Category Risk Mitigant Business Model Risk Mente system does not scale The new subscription business model effectively reduces a large one-off cost to a pay-as-you-use system, thus, making the device more affordable & scalable to a larger demographic. Slow adoption of the Mente device Neur
Slide 27: Contact Details
Contact Details Company Investor / Media Relations Peter Griffiths, Chief Executive Officer Matthew Wright peter.griffiths@mentetech.com matt@nwrcommunications.com.au Neurotech International Ltd NWR Communications Level 14, 225 St Georges Terrace Level 6, 350 Collins St Perth Western Australia 6000
Slide 28: www.neurotechinternational.com www.mentetech.com
www.neurotechinternational.com www.mentetech.com
Neurotech International — Investor Presentation (January 2019) on 6ix